Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapeutic agents for the treatment of cardiovascular diseases. The company's primary focus was on its proprietary nitroxyl (HNO) donor technology, which aimed to provide a new mechanism of action for treating heart failure by improving both contraction and relaxation of the heart muscle without increasing heart rate or oxygen consumption. Its lead candidate, CXL-1427, was an intravenous prodrug that releases nitroxyl and was primarily developed for acute decompensated heart failure. In 2015, the company was acquired by Bristol Myers Squibb to bolster their cardiovascular pipeline, with the lead asset subsequently developed as BMS-986231 (cimlanod).